메뉴 건너뛰기




Volumn 7, Issue 10, 2018, Pages

Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma

Author keywords

CD40; CTLA4; melanoma

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; B RAF KINASE; BILIRUBIN; C REACTIVE PROTEIN; CARBOPLATIN; CD40 LIGAND MONOCLONAL ANTIBODY; CHECKPOINT KINASE INHIBITOR; CP 870893; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; IBUPROFEN; IMATINIB; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; LACTATE DEHYDROGENASE; NILOTINIB; NIVOLUMAB; PACLITAXEL; PARACETAMOL; PEMBROLIZUMAB; PEPTIDE VACCINE; PROGRAMMED DEATH 1 RECEPTOR; STEROID; TICILIMUMAB; UNINDEXED DRUG; VEMURAFENIB;

EID: 85052143299     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2018.1468956     Document Type: Article
Times cited : (91)

References (30)
  • 1
    • 84928774156 scopus 로고    scopus 로고
    • The future of immune checkpoint therapy
    • Sharma P, Allison JP., The future of immune checkpoint therapy. Science. 2015;348:56–61. doi: 10.1126/science.aaa8172
    • (2015) Science , vol.348 , pp. 56-61
    • Sharma, P.1    Allison, J.P.2
  • 3
    • 84874845333 scopus 로고    scopus 로고
    • Agonistic CD40 antibodies and cancer therapy
    • Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013;19:1035–1043. doi: 10.1158/1078-0432.CCR-12-2064
    • (2013) Clin Cancer Res , vol.19 , pp. 1035-1043
    • Vonderheide, R.H.1    Glennie, M.J.2
  • 4
    • 84941615057 scopus 로고    scopus 로고
    • Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
    • Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest. 2015;125:3377–3383. doi: 10.1172/JCI80012
    • (2015) J Clin Invest , vol.125 , pp. 3377-3383
    • Buchbinder, E.1    Hodi, F.S.2
  • 5
    • 84927130807 scopus 로고    scopus 로고
    • Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
    • Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205–214. doi: 10.1016/j.cell.2015.03.030
    • (2015) Cell , vol.161 , pp. 205-214
    • Sharma, P.1    Allison, J.P.2
  • 6
    • 0034141468 scopus 로고    scopus 로고
    • Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb
    • Ito D, Ogasawara K, Iwabuchi K, Inuyama Y, Onoe K. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb. J Immunol. 2000;164:1230–1235
    • (2000) J Immunol , vol.164 , pp. 1230-1235
    • Ito, D.1    Ogasawara, K.2    Iwabuchi, K.3    Inuyama, Y.4    Onoe, K.5
  • 8
    • 84874605864 scopus 로고    scopus 로고
    • Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma
    • Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31:616–622. doi: 10.1200/JCO.2012.44.6112
    • (2013) J Clin Oncol , vol.31 , pp. 616-622
    • Ribas, A.1    Kefford, R.2    Marshall, M.A.3    Punt, C.J.4    Haanen, J.B.5    Marmol, M.6    Garbe, C.7    Gogas, H.8    Schachter, J.9    Linette, G.10
  • 9
    • 32644467549 scopus 로고    scopus 로고
    • Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206
    • Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23:8968–8977. doi: 10.1200/JCO.2005.01.109
    • (2005) J Clin Oncol , vol.23 , pp. 8968-8977
    • Ribas, A.1    Camacho, L.H.2    Lopez-Berestein, G.3    Pavlov, D.4    Bulanhagui, C.A.5    Millham, R.6    Comin-Anduix, B.7    Reuben, J.M.8    Seja, E.9    Parker, C.A.10
  • 11
    • 78549256115 scopus 로고    scopus 로고
    • Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors
    • Ruter J, Antonia SJ, Burris HA, 3rd, Huhn RD, Vonderheide RH. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther. 2010;10:983–993. doi: 10.4161/cbt.10.10.13251
    • (2010) Cancer Biol Ther , vol.10 , pp. 983-993
    • Ruter, J.1    Antonia, S.J.2    Burris, H.A.3    Huhn, R.D.4    Vonderheide, R.H.5
  • 12
    • 84877805593 scopus 로고    scopus 로고
    • Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
    • Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology. 2013;2:e23033. doi: 10.4161/onci.23033
    • (2013) Oncoimmunology , vol.2 , pp. e23033
    • Vonderheide, R.H.1    Burg, J.M.2    Mick, R.3    Trosko, J.A.4    Li, D.5    Shaik, M.N.6    Tolcher, A.W.7    Hamid, O.8
  • 14
    • 84922254940 scopus 로고    scopus 로고
    • Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma
    • Bajor DL, Xu X, Torigian DA, Mick R, Garcia LR, Richman LP, Desmarais C, Nathanson KL, Schuchter LM, Kalos M, et al. Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma. Cancer Immunol Res. 2014;2:1051–1058. doi: 10.1158/2326-6066.CIR-14-0154
    • (2014) Cancer Immunol Res , vol.2 , pp. 1051-1058
    • Bajor, D.L.1    Xu, X.2    Torigian, D.A.3    Mick, R.4    Garcia, L.R.5    Richman, L.P.6    Desmarais, C.7    Nathanson, K.L.8    Schuchter, L.M.9    Kalos, M.10
  • 15
    • 84949936992 scopus 로고    scopus 로고
    • A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma
    • Nowak AK, Cook AM, McDonnell AM, Millward MJ, Creaney J, Francis RJ, Hasani A, Segal A, Musk AW, Turlach BA, et al. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Ann Oncol. 2015;26:2483–2490. doi: 10.1093/annonc/mdv387
    • (2015) Ann Oncol , vol.26 , pp. 2483-2490
    • Nowak, A.K.1    Cook, A.M.2    McDonnell, A.M.3    Millward, M.J.4    Creaney, J.5    Francis, R.J.6    Hasani, A.7    Segal, A.8    Musk, A.W.9    Turlach, B.A.10
  • 16
    • 34247327043 scopus 로고    scopus 로고
    • An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model
    • Hunter TB, Alsarraj M, Gladue RP, Bedian V, Antonia SJ. An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model. Scand J Immunol. 2007;65:479–486. doi: 10.1111/j.1365-3083.2007.01927.x
    • (2007) Scand J Immunol , vol.65 , pp. 479-486
    • Hunter, T.B.1    Alsarraj, M.2    Gladue, R.P.3    Bedian, V.4    Antonia, S.J.5
  • 17
    • 70749083844 scopus 로고    scopus 로고
    • Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation
    • Carpenter EL, Mick R, Ruter J, Vonderheide RH. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J Transl Med. 2009;7:93. doi: 10.1186/1479-5876-7-93
    • (2009) J Transl Med , vol.7 , pp. 93
    • Carpenter, E.L.1    Mick, R.2    Ruter, J.3    Vonderheide, R.H.4
  • 19
    • 33947223664 scopus 로고    scopus 로고
    • Prospect of targeting the CD40 pathway for cancer therapy
    • Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res. 2007;13:1083–1088. doi: 10.1158/1078-0432.CCR-06-1893
    • (2007) Clin Cancer Res , vol.13 , pp. 1083-1088
    • Vonderheide, R.H.1
  • 20
    • 0030996214 scopus 로고    scopus 로고
    • The CD40 ligand. At the center of the immune universe?
    • Grewal IS, Flavell RA. The CD40 ligand. At the center of the immune universe? Immunol Res. 1997;16:59–70
    • (1997) Immunol Res , vol.16 , pp. 59-70
    • Grewal, I.S.1    Flavell, R.A.2
  • 22
    • 84961290760 scopus 로고    scopus 로고
    • Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
    • Hannani D, Vetizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015;25:208–224. doi: 10.1038/cr.2015.3
    • (2015) Cell Res , vol.25 , pp. 208-224
    • Hannani, D.1    Vetizou, M.2    Enot, D.3    Rusakiewicz, S.4    Chaput, N.5    Klatzmann, D.6    Desbois, M.7    Jacquelot, N.8    Vimond, N.9    Chouaib, S.10
  • 23
    • 84928917822 scopus 로고    scopus 로고
    • Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma
    • Patt D, Chen T-T, Berman DM, Wolchok JD
    • Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen T-T, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–1894. doi: 10.1200/JCO.2014.56.2736
    • (2015) J Clin Oncol , vol.33 , pp. 1889-1894
    • Schadendorf, D.1    Hodi, F.S.2    Robert, C.3    Weber, J.S.4    Margolin, K.5    Hamid, O.6
  • 25
    • 33750533981 scopus 로고    scopus 로고
    • Giving blood: a new role for CD40 in tumorigenesis
    • Bergmann S, Pandolfi PP. Giving blood: a new role for CD40 in tumorigenesis. J Exp Med. 2006;203:2409–2412. doi: 10.1084/jem.20061754
    • (2006) J Exp Med , vol.203 , pp. 2409-2412
    • Bergmann, S.1    Pandolfi, P.P.2
  • 26
    • 79954579274 scopus 로고    scopus 로고
    • Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody
    • Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res. 2011;17:2270–2280. doi: 10.1158/1078-0432.CCR-10-2888
    • (2011) Clin Cancer Res , vol.17 , pp. 2270-2280
    • Fransen, M.F.1    Sluijter, M.2    Morreau, H.3    Arens, R.4    Melief, C.J.5
  • 27
    • 85011955241 scopus 로고    scopus 로고
    • Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
    • Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6:664–679. doi: 10.1158/2159-8290.CD-16-0040
    • (2016) Cancer Discov , vol.6 , pp. 664-679
    • Teachey, D.T.1    Lacey, S.F.2    Shaw, P.A.3    Melenhorst, J.J.4    Maude, S.L.5    Frey, N.6    Pequignot, E.7    Gonzalez, V.E.8    Chen, F.9    Finklestein, J.10
  • 30
    • 0029851283 scopus 로고    scopus 로고
    • A note on quantifying follow-up in studies of failure time
    • Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Controlled Clinical Trials. 1996;17:343–346
    • (1996) Controlled Clinical Trials , vol.17 , pp. 343-346
    • Schemper, M.1    Smith, T.L.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.